Latest Aqueous humour Stories
A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma – an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.
Toxic Anterior Segment Syndrome (TASS) is a rare but sight threatening complication of cataract surgery.
Glaucoma â€“ the second leading cause of blindness in the world â€“ is now thought to run in families.
Glaucoma â€“ a leading cause of vision loss and blindness worldwide â€“ runs in families.
An eye under pressure appears to express a unique set of proteins that physicians hope will one day help them better diagnose and treat glaucoma.
SOUTH SAN FRANCISCO, Calif., April 5 /PRNewswire/ -- Altheos, Inc., a privately held early-stage biopharmaceutical company, announced today that it has completed a $20 million Series A financing led by Bay City Capital.
US-based biopharmaceutical company Inspire Pharmaceuticals has announced that the standard 30-day review period by the FDA relating to the company's investigational new drug application for INS117548 ophthalmic solution for the treatment of glaucoma has concluded and clinical testing can proceed.
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that the standard 30-day review period by the U.S.
- a slit in a tire to drain away surface water and improve traction.